cositecan has been researched along with dactinomycin in 1 studies
| Studies (cositecan) | Trials (cositecan) | Recent Studies (post-2010) (cositecan) | Studies (dactinomycin) | Trials (dactinomycin) | Recent Studies (post-2010) (dactinomycin) |
|---|---|---|---|---|---|
| 20 | 5 | 2 | 19,045 | 355 | 969 |
| Protein | Taxonomy | cositecan (IC50) | dactinomycin (IC50) |
|---|---|---|---|
| RAD51 | Homo sapiens (human) | 32.1 | |
| Growth factor receptor-bound protein 2 | Homo sapiens (human) | 5 | |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | 9 | |
| Growth factor receptor-bound protein 2 | Mus musculus (house mouse) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pappo, A; Paulino, AC | 1 |
1 other study(ies) available for cositecan and dactinomycin
| Article | Year |
|---|---|
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |